New drug duo tested for tough cancers
NCT ID NCT05427396
First seen Dec 08, 2025 · Last updated May 16, 2026 · Updated 22 times
Summary
This early-stage study tested a combination of two drugs (JS004 and Toripalimab) in 31 adults with advanced solid tumors like liver, esophageal, and stomach cancers that had stopped responding to standard treatments. The main goal was to check safety and side effects. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, GASTRIC ADENOCARCINOMA, CERVICAL CANCER, MSI-H COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
Conditions
Explore the condition pages connected to this study.